0000000000010633

AUTHOR

Wolfgang Jilg

showing 3 related works from this author

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccinatio…

2009

Priming a population with a pre-pandemic vaccine is being considered to maximize the response upon subsequent vaccination with a true pandemic vaccine more closely matched to the causative pandemic strain. The present study explored this prime-boost concept by evaluating different primary schedules with the pre-pandemic A/Vietnam/1194/2004(NIBRG-14) vaccine, containing 3.75 microg of HA, followed by a 6-month booster with a vaccine formulated with 3.75 microg HA of either the same strain or with A/Indonesia/05/2005(IBCDC-RG2), a heterologous strain from a different clade. In this multicentre, open, randomized study (NCT00430521) we measured immune responses in four groups (N = 48-60) of adu…

AdultMalePediatricsmedicine.medical_specialtyAdolescentCross Protectionmedicine.medical_treatmentPopulationImmunization SecondaryBooster doseAntibodies ViralYoung AdultAdjuvants ImmunologicImmunityInfluenza Humanparasitic diseasesmedicineHumansAS03educationeducation.field_of_studyBooster (rocketry)Influenza A Virus H5N1 SubtypeGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthHemagglutination Inhibition TestsMiddle AgedImmunity HumoralVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicineFemalebusinessAdjuvantVaccine
researchProduct

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants

2005

The long-term efficacy of hepatitis B vaccine, long-term effectiveness of hepatitis B immunisation programmes, immune memory induced by hepatitis B vaccine, current booster policies, and impact of hepatitis B virus mutants on immunisation programmes were reviewed at the Viral Hepatitis Prevention Board (VHPB) meeting in Sevilla, Spain, March 2004. The main focus was on universal vaccination programmes with data being presented from Italy, Saudi Arabia, Singapore, Spain, Taiwan, Thailand, The Gambia, and USA (Alaska).

Hepatitis B vaccineSettore MED/42 - Igiene Generale e ApplicataImmunization Secondarymedicine.disease_causeTimeOrthohepadnavirusparasitic diseasesHumanshepatitis B vaccination long-term efficacy virus mutantsMedicineHepatitis B VaccinesHepatitis B AntibodiesHepatitis B virusGeneral VeterinaryGeneral Immunology and MicrobiologybiologyImmunization Programsbusiness.industryPublic Health Environmental and Occupational HealthHepatitis BHepatitis Bbiology.organism_classificationmedicine.diseaseVirologyVaccinationInfectious DiseasesHepadnaviridaeDNA ViralMutationMolecular MedicineViral diseasebusinessViral hepatitisImmunologic Memorygeographic locationsVaccine
researchProduct

Frequency of CD8+ T Lymphocytes Specific for Lytic and Latent Antigens of Epstein–Barr Virus in Healthy Virus Carriers

1999

Abstract We investigated CD8 + T cell frequencies of five different Epstein–Barr virus-specific cytotoxic T lymphocyte epitopes located within proteins of the replicative cycle and the latent state in healthy long-term virus carriers with IFN-γ enzyme-linked immunospot assay. Frequencies of the HLA-A3-restricted epitope RVRAYTYSK (RVR) whose minimal length was mapped in this study to amino acid position 148–156 of the immediate-early protein BRLF1 were compared with those of a further known HLA-A3-restricted epitope within EBNA3A, RLRAEAQVK (RLR). Determination of frequencies of CD8 + T lymphocytes directed against lytic antigen epitope RVR revealed that only one of eight donors recognized …

Epstein-Barr Virus InfectionsHerpesvirus 4 HumanvirusesT cellEpitopes T-LymphocyteCD8-Positive T-LymphocytesBiologymedicine.disease_causeVirusEpitopeCell LineImmediate-Early ProteinsViral ProteinsAntigenVirologymedicineHumansCytotoxic T cellHematopoietic Stem CellsEpstein–Barr virusVirologyMolecular biologyBZLF1medicine.anatomical_structureEpstein-Barr Virus Nuclear AntigensCarrier StateTrans-ActivatorsCD8T-Lymphocytes CytotoxicVirology
researchProduct